{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T01:53:30Z","timestamp":1789869210883,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T00:00:00Z","timestamp":1380240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/cdd.2013.133","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T14:18:45Z","timestamp":1380291525000},"page":"100-112","source":"Crossref","is-referenced-by-count":84,"title":["The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia"],"prefix":"10.1038","volume":"21","author":[{"given":"J-N","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-S","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-H","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-L","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-S","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-L","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-N","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-W","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,27]]},"reference":[{"key":"BFcdd2013133_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.6004\/jnccn.2012.0103","volume":"10","author":"MR O'Donnell","year":"2012","unstructured":"O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2012; 10: 984\u20131021.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFcdd2013133_CR2","unstructured":"National cancer institute report on Acute myeloid leukemia. \n                    http:\/\/seer.cancer.gov\/csr\/1975_2009_pops09\/\n                    \n                  . Based on November 2011 SEER data submission."},{"key":"BFcdd2013133_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451\u2013458.","journal-title":"Br J Haematol"},{"key":"BFcdd2013133_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1397-3142.2003.00119.x","volume":"7","author":"MP Atlas","year":"2003","unstructured":"Atlas MP, Lipton JM . Treatment of relapsing AML following hematopoietic stem cell transplantation. Pediatr Transplant 2003; 7: 419\u2013421.","journal-title":"Pediatr Transplant"},{"key":"BFcdd2013133_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/02841860151116321","volume":"40","author":"E Kimby","year":"2001","unstructured":"Kimby E, Nygren P, Glimelius B . A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 2001; 40: 231\u2013252.","journal-title":"Acta Oncol"},{"key":"BFcdd2013133_CR6","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179\u20134187.","journal-title":"Blood"},{"key":"BFcdd2013133_CR7","first-page":"863","volume":"108","author":"U Krug","year":"2011","unstructured":"Krug U, Buchner T, Berdel WE, Muller-Tidow C . The treatment of elderly patients with acute myeloid leukemia. Dtsch Arztebl Int 2011; 108: 863\u2013870.","journal-title":"Dtsch Arztebl Int"},{"key":"BFcdd2013133_CR8","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB, Appelbaum FR, Estey EH, Bernstein ID . Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012; 119: 6198\u20136208.","journal-title":"Blood"},{"key":"BFcdd2013133_CR9","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1158\/1078-0432.CCR-04-0210","volume":"10","author":"P Bali","year":"2004","unstructured":"Bali P, George P, Cohen P, Tao J, Guo F, Sigua C et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 2004; 10: 4991\u20134997.","journal-title":"Clin Cancer Res"},{"key":"BFcdd2013133_CR10","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","volume":"105","author":"P George","year":"2005","unstructured":"George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768\u20131776.","journal-title":"Blood"},{"key":"BFcdd2013133_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3324\/haematol.11666","volume":"93","author":"E Colado","year":"2008","unstructured":"Colado E, Alvarez-Fernandez S, Maiso P, Martin-Sanchez J, Vidriales MB, Garayoa M et al. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica 2008; 93: 57\u201366.","journal-title":"Haematologica"},{"key":"BFcdd2013133_CR12","doi-asserted-by":"crossref","unstructured":"Trujillo A, McGee C, Cogle CR . Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012: 128608.","DOI":"10.1155\/2012\/128608"},{"key":"BFcdd2013133_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/bjc.2011.564","volume":"106","author":"WH Lin","year":"2012","unstructured":"Lin WH, Jiaang WT, Chen CW, Yen KJ, Hsieh SY, Yen SC et al. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br J Cancer 2012; 106: 475\u2013481.","journal-title":"Br J Cancer"},{"key":"BFcdd2013133_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jnci\/djm328","volume":"100","author":"W Zhang","year":"2008","unstructured":"Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184\u2013198.","journal-title":"J Natl Cancer Inst"},{"key":"BFcdd2013133_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0092-8674(01)00616-X","volume":"107","author":"V Ambros","year":"2001","unstructured":"Ambros V . microRNAs: tiny regulators with great potential. Cell 2001; 107: 823\u2013826.","journal-title":"Cell"},{"key":"BFcdd2013133_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrg1379","volume":"5","author":"L He","year":"2004","unstructured":"He L, Hannon GJ . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522\u2013531.","journal-title":"Nat Rev Genet"},{"key":"BFcdd2013133_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1367-5931(03)00075-9","volume":"7","author":"XS Ke","year":"2003","unstructured":"Ke XS, Liu CM, Liu DP, Liang CC . MicroRNAs: key participants in gene regulatory networks. Curr Opin Chem Biol 2003; 7: 516\u2013523.","journal-title":"Curr Opin Chem Biol"},{"key":"BFcdd2013133_CR18","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1038\/sj.onc.1210856","volume":"27","author":"IA Asangani","year":"2008","unstructured":"Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128\u20132136.","journal-title":"Oncogene"},{"key":"BFcdd2013133_CR19","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/emboj.2012.45","volume":"31","author":"S Jiang","year":"2012","unstructured":"Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S et al. A novel miR-155\/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 2012; 31: 1985\u20131998.","journal-title":"EMBO J"},{"key":"BFcdd2013133_CR20","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-04-0637","volume":"64","author":"J Takamizawa","year":"2004","unstructured":"Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753\u20133756.","journal-title":"Cancer Res"},{"key":"BFcdd2013133_CR21","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1182\/blood-2011-09-378687","volume":"119","author":"Y Li","year":"2012","unstructured":"Li Y, Vecchiarelli-Federico LM, Li YJ, Egan SE, Spaner D, Hough MR et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood 2012; 119: 4486\u20134498.","journal-title":"Blood"},{"key":"BFcdd2013133_CR22","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1182\/blood-2011-10-386235","volume":"119","author":"Z Li","year":"2012","unstructured":"Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 2012; 119: 2314\u20132324.","journal-title":"Blood"},{"key":"BFcdd2013133_CR23","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1182\/blood-2010-04-281600","volume":"116","author":"JA Pulikkan","year":"2010","unstructured":"Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S et al. C\/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 2010; 116: 5638\u20135649.","journal-title":"Blood"},{"key":"BFcdd2013133_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1476-4598-10-108","volume":"10","author":"H Zhang","year":"2011","unstructured":"Zhang H, Luo XQ, Feng DD, Zhang XJ, Wu J, Zheng YS et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 2011; 10: 108.","journal-title":"Mol Cancer"},{"key":"BFcdd2013133_CR25","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1182\/blood-2009-09-243147","volume":"115","author":"JJ Zhao","year":"2010","unstructured":"Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630\u20132639.","journal-title":"Blood"},{"key":"BFcdd2013133_CR26","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1038\/onc.2011.193","volume":"30","author":"C Braconi","year":"2011","unstructured":"Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011; 30: 4750\u20134756.","journal-title":"Oncogene"},{"key":"BFcdd2013133_CR27","first-page":"836","volume":"51","author":"Y Xiong","year":"2010","unstructured":"Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836\u2013845.","journal-title":"Hepatology"},{"key":"BFcdd2013133_CR28","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1182\/blood-2009-03-211938","volume":"114","author":"R Garzon","year":"2009","unstructured":"Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114: 5331\u20135341.","journal-title":"Blood"},{"key":"BFcdd2013133_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ccr.2010.03.008","volume":"17","author":"S Liu","year":"2010","unstructured":"Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ et al. Sp1\/NFkappaB\/HDAC\/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010; 17: 333\u2013347.","journal-title":"Cancer Cell"},{"key":"BFcdd2013133_CR30","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s11033-011-1026-5","volume":"39","author":"F Wang","year":"2012","unstructured":"Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z, Xia LY et al. miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep 2012; 39: 2713\u20132722.","journal-title":"Mol Biol Rep"},{"key":"BFcdd2013133_CR31","doi-asserted-by":"publisher","first-page":"15805","DOI":"10.1073\/pnas.0707628104","volume":"104","author":"M Fabbri","year":"2007","unstructured":"Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci 2007; 104: 15805\u201315810.","journal-title":"Proc Natl Acad Sci"},{"key":"BFcdd2013133_CR32","doi-asserted-by":"publisher","first-page":"e19518","DOI":"10.1371\/journal.pone.0019518","volume":"6","author":"G Kong","year":"2011","unstructured":"Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X . Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One 2011; 6: e19518.","journal-title":"PLoS One"},{"key":"BFcdd2013133_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11010-011-0755-z","volume":"352","author":"C Wang","year":"2011","unstructured":"Wang C, Bian Z, Wei D, Zhang JG . MiR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 2011; 352: 197\u2013207.","journal-title":"Mol Cell Biochem"},{"key":"BFcdd2013133_CR34","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2011-10-385716","volume":"119","author":"XS Wang","year":"2012","unstructured":"Wang XS, Gong JN, Yu J, Wang F, Zhang XH, Yin XL et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 2012; 119: 4992\u20135004.","journal-title":"Blood"},{"key":"BFcdd2013133_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4161\/epi.6.3.14056","volume":"6","author":"T Nguyen","year":"2010","unstructured":"Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2010; 6: 388\u2013394.","journal-title":"Epigenetics"},{"key":"BFcdd2013133_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1084\/jem.20090831","volume":"207","author":"YC Han","year":"2010","unstructured":"Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB et al. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med 2010; 207: 475\u2013489.","journal-title":"J Exp Med"},{"key":"BFcdd2013133_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbaexp.2007.03.005","volume":"1769","author":"JM Francy","year":"2007","unstructured":"Francy JM, Nag A, Conroy EJ, Hengst JA, Yun JK . Sphingosine kinase 1 expression is regulated by signaling through PI3K, AKT2, and mTOR in human coronary artery smooth muscle cells. Biochim Biophys Acta 2007; 1769: 253\u2013265.","journal-title":"Biochim Biophys Acta"},{"key":"BFcdd2013133_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1053\/j.gastro.2003.10.061","volume":"126","author":"X Li","year":"2004","unstructured":"Li X, Leu S, Cheong A, Zhang H, Baibakov B, Shih C et al. Akt2, phosphatidylinositol 3-kinase, and PTEN are in lipid rafts of intestinal cells: role in absorption and differentiation. Gastroenterology 2004; 126: 122\u2013135.","journal-title":"Gastroenterology"},{"key":"BFcdd2013133_CR39","first-page":"2973","volume":"58","author":"AX Liu","year":"1998","unstructured":"Liu AX, Testa JR, Hamilton TC, Jove R, Nicosia SV, Cheng JQ . AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 1998; 58: 2973\u20132977.","journal-title":"Cancer Res"},{"key":"BFcdd2013133_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/sj.leu.2402389","volume":"16","author":"T Decker","year":"2002","unstructured":"Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002; 16: 327\u2013334.","journal-title":"Leukemia"},{"key":"BFcdd2013133_CR41","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","volume":"110","author":"L Wang","year":"2007","unstructured":"Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T et al. Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007; 110: 2075\u20132083.","journal-title":"Blood"},{"key":"BFcdd2013133_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng.2007.30","volume":"40","author":"TC Chang","year":"2008","unstructured":"Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43\u201350.","journal-title":"Nat Genet"},{"key":"BFcdd2013133_CR43","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/jcb.22630","volume":"110","author":"JL Mott","year":"2010","unstructured":"Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME . Transcriptional suppression of mir-29b-1\/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 2010; 110: 1155\u20131164.","journal-title":"J Cell Biochem"},{"key":"BFcdd2013133_CR44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","volume":"22","author":"X Zhang","year":"2012","unstructured":"Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22: 506\u2013523.","journal-title":"Cancer Cell"},{"key":"BFcdd2013133_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nsmb.1533","volume":"16","author":"SY Park","year":"2009","unstructured":"Park SY, Lee JH, Ha M, Nam JW, Kim VN . MiR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16: 23\u201329.","journal-title":"Nat Struct Mol Biol"},{"key":"BFcdd2013133_CR46","doi-asserted-by":"publisher","first-page":"11590","DOI":"10.1158\/0008-5472.CAN-06-3613","volume":"66","author":"Y Pekarsky","year":"2006","unstructured":"Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590\u201311593.","journal-title":"Cancer Res"},{"key":"BFcdd2013133_CR47","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ncb2615","volume":"14","author":"K Tumaneng","year":"2012","unstructured":"Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 2012; 14: 1322\u20131329.","journal-title":"Nat Cell Biol"},{"key":"BFcdd2013133_CR48","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","volume":"102","author":"Q Xu","year":"2003","unstructured":"Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972\u2013980.","journal-title":"Blood"},{"key":"BFcdd2013133_CR49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/labinvest.2012.10","volume":"92","author":"L Li","year":"2012","unstructured":"Li L, Sarver AL, Alamgir S, Subramanian S . Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest 2012; 92: 571\u2013583.","journal-title":"Lab Invest"},{"key":"BFcdd2013133_CR50","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/mt.2011.48","volume":"19","author":"P Trang","year":"2011","unstructured":"Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19: 1116\u20131122.","journal-title":"Mol Ther"},{"key":"BFcdd2013133_CR51","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","volume":"137","author":"J Kota","year":"2009","unstructured":"Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005\u20131017.","journal-title":"Cell"},{"key":"BFcdd2013133_CR52","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.cell.2009.05.038","volume":"137","author":"JJ Rossi","year":"2009","unstructured":"Rossi JJ . New hope for a microRNA therapy for liver cancer. Cell 2009; 137: 990\u2013992.","journal-title":"Cell"},{"key":"BFcdd2013133_CR53","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1093\/nar\/gni178","volume":"33","author":"C Chen","year":"2005","unstructured":"Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179.","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Death & Differentiation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cdd2013133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cdd2013133","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cdd2013133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:03:40Z","timestamp":1684415020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cdd2013133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,27]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["BFcdd2013133"],"URL":"https:\/\/doi.org\/10.1038\/cdd.2013.133","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,27]]}}}